LR Health & Beauty SE published its financial results for the first six months of 2025. Sales during the first half of 2025 totaled $166.6 million, a slight decrease (0.3%) from the first half of last year. Sales during the second quarter were $80.3 million, down from $82.4 million in Q2 2024. The company attributed these declines to “subdued consumer sentiment, particularly noticeable in Western European markets.”
EBITDA during the first half of the year improved by 13.6% to $15.5 million. It is important to note that refinancing costs impacted the EBITDA results in the same period last year. Normalized EBITDA increased by 6.3% to $17.8 million in the first half of 2025, up from $16.8 million in the same period last year.
“In the first half of 2025, we focused on further enhancing the foundations for the business success of our distributors,” said Valdemaras Gordinskis, LR Health & Beauty SE Vice President Global Controlling and Investor Relations. “Our product innovations play an important role in this. Through regular product launches and the targeted expansion of our portfolio, we are opening up attractive business opportunities for our distributors in a generally challenging market environment.”
The company’s recent leadership appointments, including Jörg Körfer as CEO and Ante Franicevic as Interim Chief Financial Officer, is expected to strengthen the company’s management strategy. Franicevic brings more than two decades of senior management experience in finance to the role.
“As a newly formed leadership team, our clear goal is to continue LR’s success story as Europe’s leading social commerce company,” Körfer said. “Our Global Leader Convention in Berlin, marking the company’s 40th anniversary, and the Business Days in September provide an ideal opportunity to strengthen our engagement with our community members and to launch new business initiatives. Together with our distributors, we aim to make the company even stronger and more innovative, thereby ensuring sustainable success for LR in a challenging market environment.”
The company now expects EBITDA in 2025 to be in the range of $28 million to $31.4 million with stable revenue.
The post LR Health & Beauty Reports Financial Results for the First Half of 2025 first appeared on Direct Selling News.
